Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2004-10-29
2009-08-25
Mondesi, Robert (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S234100, C424S247100, C530S300000, C530S324000, C530S350000
Reexamination Certificate
active
07579010
ABSTRACT:
A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.
REFERENCES:
patent: 3269912 (1966-08-01), Grafe
patent: 4029765 (1977-06-01), Helting
patent: 4391801 (1983-07-01), Ng et al.
patent: 4457916 (1984-07-01), Hayashi et al.
patent: 4578270 (1986-03-01), Csizer et al.
patent: 4597966 (1986-07-01), Zolton et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4904467 (1990-02-01), Schwulera
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4985242 (1991-01-01), Sekine et al.
patent: 5118794 (1992-06-01), Grangeorge et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5401243 (1995-03-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5445817 (1995-08-01), Schneerson et al.
patent: 5466672 (1995-11-01), Kushnaryov et al.
patent: 5512547 (1996-04-01), Johnson et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5609871 (1997-03-01), Michael et al.
patent: 5618676 (1997-04-01), Hitzeman et al.
patent: 5670484 (1997-09-01), Binder
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5695956 (1997-12-01), McClane et al.
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5698536 (1997-12-01), Segall et al.
patent: 5704297 (1998-01-01), Hussain et al.
patent: 5714468 (1998-02-01), Binder
patent: 5721215 (1998-02-01), Aoki et al.
patent: 5723281 (1998-03-01), Segall et al.
patent: 5730969 (1998-03-01), Hora et al.
patent: 5756468 (1998-05-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5846929 (1998-12-01), Johnson et al.
patent: 5905143 (1999-05-01), Johnson et al.
patent: 5908825 (1999-06-01), Fasano et al.
patent: 5919463 (1999-07-01), Thomas, Jr. et al.
patent: 5919665 (1999-07-01), Williams
patent: 5942242 (1999-08-01), Mizushima et al.
patent: 5945098 (1999-08-01), Sarno et al.
patent: 5997856 (1999-12-01), Hora et al.
patent: 6034221 (2000-03-01), Berezenko et al.
patent: 6051239 (2000-04-01), Simpson et al.
patent: 6087327 (2000-07-01), Pearce et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6150133 (2000-11-01), Mead et al.
patent: 8238664 (2001-05-01), Hellerbrand et al.
patent: 6346519 (2002-02-01), Petrus
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6787517 (2004-09-01), Gil et al.
patent: 6992172 (2006-01-01), Chang et al.
patent: 7211261 (2007-05-01), Moyer et al.
patent: 2005/0244358 (2005-11-01), Ochoa
patent: 1215064 (1999-04-01), None
patent: 1215084 (1999-04-01), None
patent: 0 123 291 (1984-10-01), None
patent: 0123291 (1984-10-01), None
patent: 0330451 (1989-08-01), None
patent: 0361991 (1990-04-01), None
patent: 0361991 (1999-12-01), None
patent: 1273593 (2002-05-01), None
patent: WO 96/11699 (1996-04-01), None
patent: WO 96 37515 (1996-11-01), None
patent: WO 97/35604 (1997-10-01), None
patent: 00/15245 (2000-03-01), None
patent: WO 00/15245 (2000-03-01), None
patent: WO00/15245 (2000-03-01), None
patent: WO00/15245 (2000-03-01), None
patent: WO 01/54711 (2001-01-01), None
patent: WO 01/26736 (2001-04-01), None
Label, 14-7683-006, Bayer Corporation,Albumin(Human) 20%.USP Plasbumin-20, May 1998.
A. Kohl, et al., Comparison of the effect of botulinum ioxin A (Botox®)with the highly-purified neurotoxin(NT201)in the extensor digitorum brevis muscle test. Mov Disord 2000;15(suppl 3):165.
Marjama-Lyons. J. et al..Tremor-Predominant Parkinson's Disease, Drugs & Aging Apr. 16, 2000(4): 273-278.
Naumann. M. et al..Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other, hyperhidrotic conditions. European Journal of Neurology 1999. 6 (suppl 4): S111-S115.
Peters, T., Jr.,All About Albumin Biochemistry, Genetics and Medical Applications. Academic Press (1996). pp. 295 & 298.
Peters, T., Jr., Chapter 7.Practical Aspects: Albumin in the Laboratoryof All About Albumin. biochemistry. genetics. and medical applications pp. 298-305. Academic Press 1996.
Ragona, R.M., et al.,Management of Parotila Siolocele with Betulinum Toxin, Laryngoscope 1999. Aug. 10981: 1344-1346.
Blgalke, H., et.;Factors influencing Potency of Botulinum Toxin In Man; Society for Neuroscience, vol. 23 (1997); No. 870.10; p. 2234.
Brin, M.F., et al.; Botulinum Toxin; Dangerous Terminology Errors;Journal of the Royal Society of Medicine: Aug. 1993; vol. 86; p. 493-494.
British Pharmacopoeia 1999;Hydroxyethyicellulose; p. 766-768.
Carpenter, J.F. et al.; Interactions of Stabilizing Additives with Proteins During Freeze-Thawing and Freeze-Drying;International Symposium on Biological Product Freeze-Drying and Formulation, Oct. 24-26, 1990; S. Jarger AG (1992); pp. 225-239.
European Pharmacopoeia 1999;Hydroxyethylcellulose; printed off CD Rom; p. 1-7.
Gartian, M.G., et al.;Crystalline Preparation of Botulinum Toxin Type A(Botox): Degradation In Potency with Storage; Otolaryngology-Head and Neck Surgery; (Feb. 1993); vol. 108, No. 2; p. 135-140.
Goodnaugh, M.C., et al.; Stabilization of Botulinum Toxin Type A during Lyophillzation;Appl. Environ. Microbiol.; Oct. 1992; vol. 58, No. 10; p. 3426-3428.
Kobayashi, K., et al.; The Development of Recombination Human Serum Albumin;Therapeutic Apheresis; 1998, vol. 2, No. 4; p. 257-262.
Material Safety Data Sheet, Product #434965, Printed Aug. 8, 1999; 5 pages.
Melling, J. et al.;Clostridium Botulinum Toxins: Nature and Preparation for Clinical Use; Eye (1988) 2:16-23.
Ohtani, W., et al.;Physicochemical and Immunochemical Properties of Recombinant Human Serum Albumin from Pichia Pastoris; Analytical Biochemistry; 1998; Article No. AB972480; No. 258; p. 56-62.
Package Insert Y36-002-345; DuPont Pharma; HESPAN®; 2 pages.
Porter, C.J.H.; Drug Delivery to the Lymphatic System;Critical Reviews™ In Therapeutic Drug Carrier Systems; 1997: 14(4); p. 333-383.
Salloia, M., et al.; Use of the KIADH4 Promoter for Ethanol-Dependent Production of Recombinant Human Serum Albumin In Kluyveromyces lactis;Appl. Environ. Microbiol.; Jan. 1999; vol. 65, No. 1; p. 53-60.
Schantz, E.J. et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine;Microbiological Reviews; Mar. 1992; vol. 56, No. 1; 80-99.
Schantz, E.J. et al.; Standardized Assay for Clostridium Botulinum Toxins;Journal of the AOAC; 1978; vol. 81, No. 1; 96-99.
Schantz, E.J.; Use of Crystalline Type A Botulinum Toxin In Medical Research;Biomedical Aspects of Botulism; Academic Press (1981); pp. 143-150.
Schmidt, J.J., et al.; Endoproteinase Activity of Type A Botulinum Neurotoxin: Substrate Requirements and Activation by Serum Albumin;Journal of Protein Chemistry; 1999; vol. 16, No. 1; p. 18-26.
Sigma 1999 Catalog;Biochemicals and Reagents for Life Science Research; pp. 187, 188 and 237.
Summary Basis of Approval (Apr. 12, 1999), OB-NDA 20-0952; 4 pages.
USP 23-NF 18, Supp. 10;Hydroxyethyl Cellulose; printed off CD Rom; p. 1-2.
Wohlfarth, H., et al.; Effect of Dilution on Activity of Commercial Preparations of Botulinum Toxin A In Marr;Society for Neuroscience, vol. 23 (1997); No. 870.11; p. 2234.
Carruthers, Alastair & Jean; Toxins 99, New Information About the Botulinum Neurotoxins;Dermatol Surg2000;26(3): pp. 174-178.
Singh, B.R.;Critical Aspects of Bacterial Protein Toxins; Natural Toxins II(1996); Plenum Press, New York; pp. 63-84.
Sloop, Richard R., et al.; Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use;Neurology 48; Jan. 1997, pp. 249-253.
Encinar et al, FEBS Letters, 429, 1998, 78.
Gul et al., Botulinum Toxin Injection in the Gastric Wall Reduces Body Weight and Food Intake in Rats,Aliment Pharmacol Ther., 14(6): 829-834 (2000).
Gassner et al.,Plast. Reconst. Surg., 105(6): 1948-1955 (2000).
Inagl et al., Physiologic Assessment of Botulinum Toxin Effects In the Rat Larynx,Laryngoscope, 108(7): 1048-1054 (1998).
Cohen and Thompson, Use of Botulinum Toxin to Laterali
Allergan Inc.
Donovan Stephen
Ford Vanessa L.
Mondesi Robert
Nassif Claude L.
LandOfFree
Botulinum toxin pharmaceutical compositions with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin pharmaceutical compositions with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin pharmaceutical compositions with a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098605